On April 22, 2026 Amplia Therapeutics limited (ASX:ATX | OTCQB:INNMF), ("Amplia" or the "Company") reported that an oral presentation highlighting mature data from the Company’s ACCENT trial in metastatic pancreatic cancer is being delivered today at the annual meeting of the AACR (Free AACR Whitepaper). The presentation includes more detailed analysis of the recently reported data from the ACCENT study, which is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation is included as part of a mini-symposium entitled Advances in Precision Oncology being held in the San Diego Convention Center, San Diego USA, and will be delivered by Amplia’s Director of Translational Biology, Dr Terrie-Anne Cock, at 3:44 pm local time. A copy of the slides is included with this announcement.
The key points from the presentation are:
Narmafotinib displays a manageable toxicity profile, with no significant tolerability burden over chemotherapy alone
Independent (central) reading of data identified 5 confirmed Complete Responses (CR’s) from 64 patients, an 8% CR rate compared to a 0.2% rate for chemotherapy alone
A response rate of 36% is observed (23 of 64 patients); 42% if unconfirmed responses included
A Disease Control Rate (DCR) of 70% was determined, compared to 50% for chemotherapy alone
Median overall survival (mOS) was found to be 11.1 months, while median progression-free survival (mPFS) was 7.7 months, both showing improvements of over two months compared to chemotherapy alone
A trend to improved Overall Survival is observed when comparing Stable Disease, Partial Response and Complete Response patients
The combined efficacy data is superior to chemotherapy alone across all measures despite the intermittent narmafotinib dosing schedule employed (12 days of each 28 day treatment cycle)
Subsequent trials will employ a daily dosing regimen of narmafotinib given the tolerability observed to date, which may lead to improved responses
Dr Chris Burns, CEO and Managing Director of Amplia, commented, "These extremely promising clinical responses demonstrate the potential narmafotinib has in the treatment of this terrible disease. We are now focused on building on this promising data with additional clinical studies, including a pivotal study based on the ACCENT trial, as well as combination studies with the exciting new class of drugs called kRAS inhibitors."
(Press release, Amplia Therapeutics, APR 22, 2026, View Source [SID1234664708])